Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched, including oligodendrocytes; strongest in neuroendocrine cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 724 | 0.70 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13095
Sealed predictions
- NKX2-2 in dopamine neurons, braak+0.27 (p 0.487) → +0.33 (p 0.385)receipt 13103
- NKX2-2 in oligodendrocytes, braak-0.03 (p 0.946) → +0.30 (p 0.428)receipt 13102
Swarm cases
receipt 13103: NKX2-2 in dopamine neurons, braak
- power
- full sample +0.37 (p 0.135, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.099, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.105, n 18). could be the mix.
- skeptic
- leave-one-out range +0.29 to +0.47, sign flips 0; without severely affected donors +0.37 (p 0.135, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NKX2-2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 13102: NKX2-2 in oligodendrocytes, braak
- power
- full sample +0.04 (p 0.874, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.814, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.11 (p 0.652, n 18). could be the mix.
- skeptic
- leave-one-out range -0.08 to +0.16, sign flips 5; without severely affected donors +0.04 (p 0.874, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NKX2-2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts